117 related articles for article (PubMed ID: 37044037)
1. Investigating combination benefit of PD1 and LAG3 co-blockade using an engineered cellular bioassay.
Bhagwat B; de Waal Malefyt R; Willingham A
Int Immunopharmacol; 2023 Jun; 119():109566. PubMed ID: 37044037
[TBL] [Abstract][Full Text] [Related]
2. Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction.
Bhagwat B; Cherwinski H; Sathe M; Seghezzi W; McClanahan TK; de Waal Malefyt R; Willingham A
J Immunol Methods; 2018 May; 456():7-14. PubMed ID: 29427592
[TBL] [Abstract][Full Text] [Related]
3. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model.
Huang RY; Eppolito C; Lele S; Shrikant P; Matsuzaki J; Odunsi K
Oncotarget; 2015 Sep; 6(29):27359-77. PubMed ID: 26318293
[TBL] [Abstract][Full Text] [Related]
4. Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors.
Natoli M; Hatje K; Gulati P; Junker F; Herzig P; Jiang Z; Davydov II; Germann M; Trüb M; Marbach D; Zwick A; Weber P; Seeber S; Wiese M; Lardinois D; Heinzelmann-Schwarz V; Rosenberg R; Tietze L; Mertz KD; Umaña P; Klein C; Codarri-Deak L; Kao H; Zippelius A
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319064
[TBL] [Abstract][Full Text] [Related]
5. The multi-specific V
Edwards CJ; Sette A; Cox C; Di Fiore B; Wyre C; Sydoruk D; Yadin D; Hayes P; Stelter S; Bartlett PD; Zuazo M; Garcia-Granda MJ; Benedetti G; Fiaska S; Birkett NR; Teng Y; Enever C; Arasanz H; Bocanegra A; Chocarro L; Fernandez G; Vera R; Archer B; Osuch I; Lewandowska M; Surani YM; Kochan G; Escors D; Legg J; Pierce AJ
Br J Cancer; 2022 May; 126(8):1168-1177. PubMed ID: 34969998
[TBL] [Abstract][Full Text] [Related]
6. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8
Kim HD; Song GW; Park S; Jung MK; Kim MH; Kang HJ; Yoo C; Yi K; Kim KH; Eo S; Moon DB; Hong SM; Ju YS; Shin EC; Hwang S; Park SH
Gastroenterology; 2018 Dec; 155(6):1936-1950.e17. PubMed ID: 30145359
[TBL] [Abstract][Full Text] [Related]
7. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
Front Immunol; 2018; 9():1955. PubMed ID: 30214445
[No Abstract] [Full Text] [Related]
8. Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy.
Andrews LP; Cillo AR; Karapetyan L; Kirkwood JM; Workman CJ; Vignali DAA
Clin Cancer Res; 2022 Dec; 28(23):5030-5039. PubMed ID: 35579997
[TBL] [Abstract][Full Text] [Related]
9. Effects of immune checkpoint blockade on antigen-specific CD8
Ogando-Rivas E; Castillo P; Jones N; Trivedi V; Drake J; Dechkovskaia A; Candelario KM; Yang C; Mitchell DA
Microbiol Immunol; 2022 May; 66(5):201-211. PubMed ID: 35150167
[TBL] [Abstract][Full Text] [Related]
10. LAG3 Regulates T Cell Activation and Plaque Infiltration in Atherosclerotic Mice.
Mulholland M; Kritikou E; Katra P; Nilsson J; Björkbacka H; Lichtman AH; Rodriguez A; Engelbertsen D
JACC CardioOncol; 2022 Dec; 4(5):635-645. PubMed ID: 36636446
[TBL] [Abstract][Full Text] [Related]
11. LAG3 (CD223) as a cancer immunotherapy target.
Andrews LP; Marciscano AE; Drake CG; Vignali DA
Immunol Rev; 2017 Mar; 276(1):80-96. PubMed ID: 28258692
[TBL] [Abstract][Full Text] [Related]
12. CD28 affects the earliest signaling events generated by TCR engagement.
Tuosto L; Acuto O
Eur J Immunol; 1998 Jul; 28(7):2131-42. PubMed ID: 9692882
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint-Related Gene Polymorphisms Are Associated With Primary Immune Thrombocytopenia.
Wang S; Zhang X; Leng S; Xu Q; Sheng Z; Zhang Y; Yu J; Feng Q; Hou M; Peng J; Hu X
Front Immunol; 2020; 11():615941. PubMed ID: 33584705
[TBL] [Abstract][Full Text] [Related]
14. CD28 family of receptors on T cells in chronic HBV infection: Expression characteristics, clinical significance and correlations with PD-1 blockade.
Tang ZS; Hao YH; Zhang EJ; Xu CL; Zhou Y; Zheng X; Yang DL
Mol Med Rep; 2016 Aug; 14(2):1107-16. PubMed ID: 27314219
[TBL] [Abstract][Full Text] [Related]
15. Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC
Zhang J; Larrocha PS; Zhang B; Wainwright D; Dhar P; Wu JD
J Immunother Cancer; 2019 Aug; 7(1):223. PubMed ID: 31446896
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
[TBL] [Abstract][Full Text] [Related]
17. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
[TBL] [Abstract][Full Text] [Related]
18. Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer.
Hu Y; Paris S; Bertolet G; Barsoumian HB; He K; Sezen D; Chen D; Wasley M; Silva JD; Mitchell JA; Voss TA; Masrorpour F; Leyton CK; Yang L; Leuschner C; Puebla-Osorio N; Gandhi S; Nguyen QN; Cortez MA; Welsh JW
J Nanobiotechnology; 2022 Sep; 20(1):417. PubMed ID: 36123677
[TBL] [Abstract][Full Text] [Related]
19. Both CD28 ligands CD80 (B7-1) and CD86 (B7-2) activate phosphatidylinositol 3-kinase, and wortmannin reveals heterogeneity in the regulation of T cell IL-2 secretion.
Ueda Y; Levine BL; Huang ML; Freeman GJ; Nadler LM; June CH; Ward SG
Int Immunol; 1995 Jun; 7(6):957-66. PubMed ID: 7577804
[TBL] [Abstract][Full Text] [Related]
20. Contribution of interleukin-12 (IL-12) and the CD28/B7 and CD40/CD40 ligand pathways to the development of a pathological T-cell response in IL-10-deficient mice.
Wille U; Villegas EN; Craig L; Peach R; Hunter CA
Infect Immun; 2002 Dec; 70(12):6940-7. PubMed ID: 12438373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
